argenx SE (NASDAQ:ARGX) Receives $658.39 Consensus Price Target from Brokerages

Shares of argenx SE (NASDAQ:ARGX) have earned a consensus rating of “Moderate Buy” from the twenty-two ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $658.39.

Several equities research analysts have recently commented on ARGX shares. Wells Fargo & Company upped their price target on shares of argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. Citigroup upped their price target on shares of argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Raymond James reaffirmed a “strong-buy” rating and set a $605.00 price target on shares of argenx in a research report on Thursday, October 10th. Evercore ISI increased their target price on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $652.19 on Friday. argenx has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The business has a 50-day simple moving average of $624.24 and a two-hundred day simple moving average of $561.49. The firm has a market cap of $39.37 billion, a price-to-earnings ratio of -741.13 and a beta of 0.59.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. As a group, research analysts predict that argenx will post 2.78 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Cromwell Holdings LLC boosted its position in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of argenx by 47.5% during the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after acquiring an additional 56 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of argenx during the 2nd quarter valued at approximately $76,000. SG Americas Securities LLC boosted its position in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares during the last quarter. Finally, Fulton Bank N.A. bought a new position in shares of argenx during the 4th quarter valued at approximately $226,000. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.